Amphotericin B liposomal indications and usage: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) |
Gerald Chi (talk | contribs) |
||
| Line 9: | Line 9: | ||
*:Empirical therapy for presumed fungal infection in febrile, [[Febrile neutropenia|neutropenic fever]] patients. | *:Empirical therapy for presumed fungal infection in febrile, [[Febrile neutropenia|neutropenic fever]] patients. | ||
*:Treatment of [[cryptococcal meningitis]] in [[HIV]] infected patients. | *:Treatment of [[cryptococcus|cryptococcal]] [[meningitis]] in [[HIV]] infected patients. | ||
*:Treatment of patients with [[Aspergillus]] species, Candida species and/or [[Cryptococcus]] species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. | *:Treatment of patients with [[Aspergillus]] species, Candida species and/or [[Cryptococcus]] species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. | ||
Revision as of 05:16, 12 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Indications and Usage
AmBisome is indicated for the following:
- Empirical therapy for presumed fungal infection in febrile, neutropenic fever patients.
- Treatment of cryptococcal meningitis in HIV infected patients.
- Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate.
- Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with AmBisome, relapse rates were high following initial clearance of parasites.[1]
References
Adapted from the FDA Package Insert.